Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20877628 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL21107629 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL21107870 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24378402 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL12744626 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL18806199 | 0.96 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL537820 | 0.85 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL21451248 | 0.82 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL12942916 | 0.80 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL4214214 | 0.79 | HTR2C (0.42) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | VESPER BIO APS (DK) | 2023-05-11 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. | 2013-04-04 | — | — | US | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
| US-7576098-B2 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576098-B2 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-4160094-A | Tetrahydroquinoline derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | ADRA2A 3903/4885ADRA2B 2813/4885ADRA2C 2993/4885 |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | ADRA2A 211/4885ADRA2B 165/4885ADRA2C 193/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ADRA2A 3031/4885ADRA2B 2417/4885ADRA2C 3163/4885 |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | ADRA2A 3929/4885ADRA2B 4062/4885ADRA2C 4037/4885 |
| US-20230144901-A1 | SORTILIN ANTAGONISTS FOR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | SORT1, SCARB1, NRP1 | ADRA2A 1916/4885ADRA2B 1473/4885ADRA2C 2410/4885 |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | RNASE1, HAVCR2, CTRL | ADRA2A 4768/4885ADRA2B 4578/4885ADRA2C 4352/4885 |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | HAVCR2, SPINT2, RNASE1 | ADRA2A 4720/4885ADRA2B 4470/4885ADRA2C 4271/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | ADRA2A 4811/4885ADRA2B 4777/4885ADRA2C 4741/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ADRA2A 168/4885ADRA2B 294/4885ADRA2C 481/4885 |
| US-20130085283-A1 | GERANYLGERANYLACETONE DERIVATIVES | GGPS1, FNTA, GNPAT | ADRA2A 231/4885ADRA2B 303/4885ADRA2C 453/4885 |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | SORT1, NTSR2, SLC17A5 | ADRA2A 2481/4885ADRA2B 2015/4885ADRA2C 2870/4885 |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ADRA2A 3031/4885ADRA2B 2417/4885ADRA2C 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.